This is the only guidance Trilogy have given
Outlook
TIL expects underlying revenue growth in FY18 to be consistent with FY17 for each segment of the business.
TIL Group EBITDA will continue to grow, despite gross margin compression as a result of higher raw material prices within Trilogy skincare.
Consistent with prior years, we expect revenue and EBITDA to be skewed towards the second half.
As long as they aren't too far away from that (whatever it means) no need for disclosure. However hopefully they will be more specific at the ASM like last year when they gave what H1 was likely to be and a broad range for FY revenues and ebitda. Remember that, sounded great on % ages but so wishy washy the share price collapsed big time.
Share price heading to 5 bucks wasn't it this time last year when no news was good news I believe
Bookmarks